423 related articles for article (PubMed ID: 28326600)
21. Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent.
Agahozo MC; Westenend PJ; van Bockstal MR; Hansum T; Giang J; Matlung SE; van Deurzen CHM
Mod Pathol; 2020 Sep; 33(9):1773-1782. PubMed ID: 32341499
[TBL] [Abstract][Full Text] [Related]
22. Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.
Khoury T; Quinn M; Tian W; Yan L; Zhan H
Histopathology; 2022 Jan; 80(2):291-303. PubMed ID: 34379814
[TBL] [Abstract][Full Text] [Related]
23. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
[TBL] [Abstract][Full Text] [Related]
24. Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers.
Lee SJ; Hwang CS; Kim YK; Lee HJ; Ahn SJ; Shin N; Lee JH; Shin DH; Choi KU; Park DY; Lee CH; Huh GY; Sol MY; Lee HJ; Gong G; Kim JY; Kim A
Cancer Res Treat; 2017 Apr; 49(2):313-321. PubMed ID: 27456948
[TBL] [Abstract][Full Text] [Related]
25. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ.
Toss MS; Miligy IM; Haj-Ahmad R; Gorringe KL; AlKawaz A; Mittal K; Ellis IO; Green AR; Rakha EA
Histopathology; 2019 Jun; 74(7):1025-1035. PubMed ID: 30725481
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer.
Chin Y; Janseens J; Vandepitte J; Vandenbrande J; Opdebeek L; Raus J
Anticancer Res; 1992; 12(5):1463-6. PubMed ID: 1332579
[TBL] [Abstract][Full Text] [Related]
27. Tumor thickness and histological features as predictors of invasive foci within preoperatively diagnosed ductal carcinoma in situ.
Mori K; Takeda M; Kodama Y; Kiyokawa H; Yasojima H; Mizutani M; Otani Y; Morikawa N; Masuda N; Mano M
Hum Pathol; 2017 Jun; 64():145-155. PubMed ID: 28434924
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ.
Toss M; Miligy I; Gorringe K; Mittal K; Aneja R; Ellis I; Green A; Rakha E
J Clin Pathol; 2020 Feb; 73(2):76-82. PubMed ID: 31444238
[TBL] [Abstract][Full Text] [Related]
30. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance.
Althobiti M; Aleskandarany MA; Joseph C; Toss M; Mongan N; Diez-Rodriguez M; Nolan CC; Ashankyty I; Ellis IO; Green AR; Rakha EA
Histopathology; 2018 Dec; 73(6):887-896. PubMed ID: 29947077
[TBL] [Abstract][Full Text] [Related]
32. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
Kim M; Choi HY; Woo JW; Chung YR; Park SY
Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
[TBL] [Abstract][Full Text] [Related]
33. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
Fang Y; Wu J; Wang W; Fei X; Zong Y; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
Oncotarget; 2016 Sep; 7(39):64182-64190. PubMed ID: 27577080
[TBL] [Abstract][Full Text] [Related]
34. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
35. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
[TBL] [Abstract][Full Text] [Related]
36. Antigen-Presenting Intratumoral B Cells Affect CD4
Bruno TC; Ebner PJ; Moore BL; Squalls OG; Waugh KA; Eruslanov EB; Singhal S; Mitchell JD; Franklin WA; Merrick DT; McCarter MD; Palmer BE; Kern JA; Slansky JE
Cancer Immunol Res; 2017 Oct; 5(10):898-907. PubMed ID: 28848053
[TBL] [Abstract][Full Text] [Related]
37. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial.
Schiza A; Thurfjell V; Stenmark Tullberg A; Olofsson H; Lindberg A; Holmberg E; Bremer T; Micke P; Karlsson P; Wärnberg F; Strell C
Eur J Cancer; 2022 Jun; 168():128-137. PubMed ID: 35236568
[TBL] [Abstract][Full Text] [Related]
38. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival.
Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B
Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast.
Yonekura R; Osako T; Iwase T; Ogiya A; Ueno T; Kitagawa M; Ohno S; Akiyama F
Breast Cancer Res Treat; 2019 Feb; 174(1):103-111. PubMed ID: 30474777
[TBL] [Abstract][Full Text] [Related]
40. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence.
Chen XY; Thike AA; Koh VCY; Nasir NDM; Bay BH; Tan PH
Virchows Arch; 2021 Apr; 478(4):679-686. PubMed ID: 33140128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
